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Abstract
Background: Transplantation of cardiosphere-derived cells (CDCs) has been shown to exert a therapeutic effect in
patients with myocardial infarction (MI). However, poor survival of transplanted CDCs limits their beneficial effect.
Metformin (MET) activates AMP-activated protein kinase (AMPK) which is associated with cell survival. The aim of
this study is to determine whether MET improves CDC survival in the transplantation microenvironment and
enhances the therapeutic effect of CDC transplantation against MI.
Methods: CDCs were isolated and expanded from transgenic β-actin-GFP mice. CDCs were pretreated with
MET and intramyocardially injected into wild-type C57 mouse heart with MI injury. The survival of CDCs was
quantified, and the infarct size and cardiac function of treated hearts were evaluated.
Results: CDC transplantation modestly reduced infarct size and improved cardiac function in the post-MI
heart, which was further improved by MET treatment. MET pretreatment significantly increased the survival
of CDCs transplanted into the myocardium. MET also reduced CDC apoptosis induced by oxidative stress in
vitro. The anti-apoptotic effect of MET was blocked by the AMPK inhibitor compound C. MET increased AMPK
phosphorylation and upregulated endothelial nitric oxide synthase (eNOS) in CDCs under oxidative stress,
which might be associated with the anti-apoptotic effect of MET.
Conclusions: MET improves the survival of transplanted CDCs in the myocardium, thereby enhancing their
therapeutic effect against MI injury. The pro-survival function of MET on CDCs might be associated with an
AMPK-eNOS-dependent mechanism.
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Background
Myocardial infarction (MI) is a major severe heart
disease that threatens human health worldwide. The
substantial loss of functional cardiomyocytes contributes
to the pathogenesis of the disease, leading to cardiac fail-
ure. Stem cell therapy offers possibilities for restoring
lost myocardium and cardiac function. Multiple cell
types, including bone marrow-derived cells and adipose
tissue-derived cells, have shown modest therapeutic
effect on post-MI patients [1]. Another cell type
which has been applied to clinical trials is
cardiosphere-derived cells (CDCs), which showed pro-
tective and regenerative capacity in both post-MI ani-
mal models and patients [1, 2]. Autologous CDCs
decreased scar size, increased viable myocardium, and
improved cardiac function in patients [1]. Transplant-
ation of embryonic stem cell- or induced pluripotent
stem cell-derived cells has shown promising effect in
post-MI animals [3, 4], although risks of
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tumorigenesis and arrhythmia currently limit their
application in patients.
Irrespective of the cell types used for transplantation,
effective cardioprotection and cardiac muscle regener-
ation are hindered by the poor survival of transplanted
cells in the infarcted myocardium, which is high in
inflammatory factors and free radicals [5]. Genetic
manipulation of pro-survival genes such as prolyl
hydroxylase domain protein 2, Akt, Bcl-2, SDF-1, and
chemokine receptor 1 have improved the viability of
transplanted stem cells in animal studies [6], but these
gene targets are difficult to interfere with in the clinical
setting thus far. An alternative approach is to identify a
known medicine, which has been used in clinics, to
improve the stem cell survival thereby enhancing the
therapeutic efficacy.
Metformin (MET), a first-line antidiabetic medication
for the treatment of type 2 diabetes, has been reported
to inhibit the mitochondrial respiratory chain and acti-
vate AMP-activated protein kinase (AMPK). AMPK can
stimulate fatty acid oxidation, promote glucose trans-
port, accelerate glycolysis, and inhibit both triglyceride
and protein synthesis. AMPK stimulation promotes
cardiomyocyte cell survival through a mitochondrial
apoptotic mechanism [7]. MET attenuates oxidative
stress-induced cardiomyocyte apoptosis and prevents the
progression of heart failure in dogs, through a mechanism
of activating AMPK [8]. MET also exerts a cardiopro-
tective effect against doxorubicin-induced cardiotoxi-
city [9, 10]. Furthermore, MET is found to attenuate
pulmonary inflammation in animals [11]. Given the
anti-apoptotic effect and the potential for reducing
inflammation, we here test if MET increases the sur-
vival of stem cells in the harsh transplantation envir-
onment of the ischemic heart. In the present study,
MET treatment was combined with CDC transplant-
ation in the post-MI mouse hearts. The therapeutic
effect against MI injury was evaluated, and the under-
lying mechanisms were further explored.
Methods
Ethics statement
Male wild-type C57 mice were purchased from the
Laboratory Animal Center of Daping Hospital, and
transgenic β-actin-GFP mice (C57BL/6-Tg (CAG-EGFP)
C14-Y01-FM131Osb) were purchased from the Jackson
Laboratory, USA. All experimental procedures using the
animals were carried out in accordance with the regula-
tions of the Animal Care and Use Committee of the
Third Military Medical University, China. All animal
protocols were approved by the Medical Ethics Commit-
tee of the Third Military Medical University (Permit
Number: 2012[13]). All efforts were made to minimize
animal suffering.
Culture and characterization of mouse CDCs
Mouse CDCs with transgenic green fluorescent protein
(GFP) labeling were obtained and expanded with a
protocol similar to that previously reported [12]. GFP
labeling was used for tracing the cell fate of CDCs post-
transplantation. Briefly, heart tissues of 4-month-old
transgenic β-actin-GFP mice were cut into fragments
<1 mm3, washed, and partially digested with trypsin
(0.05%; GIBCO). These tissue fragments were cultured
as cardiac explants on fibronectin-coated (20 mg/mL;
Sigma) dishes in 2 mL cardiac explant media (CEM;
Iscove’s modified Dulbecco’s medium (IMDM) supple-
mented with 20% fetal bovine serum (FBS) and
0.1 mmol/L 2-mercaptoethanol). After a variable period
of growth, the loosely adherent cells surrounding the ex-
plant (cardiac outgrowth) were harvested using mild en-
zymatic digestion (0.05% trypsin/EDTA) and dispensed
to poly-D-lysine-coated dishes. Several days later, cardio-
spheres were harvested, plated on fibronectin-coated
flasks, and cultured in cardiosphere growth medium
(CGM; Dulbecco’s modified Eagle’s medium (DMEM)/
F12 supplemented with 35% IMDM, 7% FBS, 29.2 mg/
mL L-glutamine, 0.1 mmol/L 2-mercaptoethanol, 2% B27
supplement, 25 ng/mL cardiotrophin, 20 ng/mL basic
fibroblast growth factor (bFGF), 10 ng/mL epidermal
growth factor (EGF), and 5 U thrombin) to generate
CDCs. The characterization of CDCs was investigated
by flow cytometry. CDCs were incubated with antibodies
against CD29, CD105, CD90, CD31, CD45, and CD34
for 30 min. Isotype-identical antibodies served as a nega-
tive control. Quantitative analysis was performed using a
BD Accuri™ C6 Cytometer and FlowJo software.
Mouse MI model and intramyocardial injection of CDCs
Animals were randomly allocated into groups with differ-
ent treatments. The mouse MI model was performed in
4-month-old wild-type C57 mice according to the
methods we described previously [6]. Under anesthesia
with isoflurane inhalation, permanent ligation of the left
anterior descending (LAD) coronary artery was made, and
CDCs were injected intramyocardially. The LAD artery
was permanently ligated with 7-0 silk suture under direct
vision. Sham-operated mice were subjected to the same
surgical procedures except with a tied suture. Using a
similar protocol to that previously reported [13], MET
was intraperitoneally injected once a day at a dosage of
125 mg/kg for 7 days (the first dose 6 h before MI injury).
For cell transplantation, C57 mice were subjected to an
intramyocardial injection immediately after MI injury at
four points in the infarct border zone with 40 μL
phosphate-buffered saline (PBS) containing 1 × 105 CDCs.
MET was used to pretreat CDCs (dissolved in PBS at
100 μmol/L containing the CDCs before transplantation)
and intraperitoneally injected into the recipient animal.
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Echocardiography analysis
Echocardiography was performed (GE vivid 7 dimen-
sion) to determine cardiac structure and function in
anesthetized mice. Mice underwent echocardiography at
4 weeks after surgery. After the induction of anesthesia
by inhalation of isoflurane, the hearts were imaged two
dimensionally (2D) in long-axis views at the level of the
greatest left ventricular (LV) diameter. Left ventricular
ejection fraction (LVEF) was automatically calculated by
the echocardiography software using Simpson’s method.
EF% was calculated as ((LVVd – LVVs)/LVVd) × 100,
where LVVd is left ventricular end-diastolic volume (μL)
and LVVs is left ventricular end-systolic volume (μL).
Left ventricular fractional shortening (FS) was calculated
as ((LVDd – LVDs)/LVDd) × 100, where LVDd is left
ventricular end-diastolic dimension (mm) and LVDs is
left ventricular end-systolic dimension (mm). Echocar-
diographic data were conducted and analyzed by blinded
investigators.
Quantification of CDC survival
To quantify the survival rate of post-transplanted CDCs,
heart cells were isolated from the mouse heart at differ-
ent time points after CDC transplantation using a
method of enzymatic digestion [6]. Briefly, heparinized
animals were anesthetized and the hearts were rapidly
mounted to a langendorff apparatus. The hearts were
perfused retrogradely with Ca2+-free normal Tyrode’s so-
lution containing 1 mg/mL collagenase II (Roche) and
0.1 mg/mL protease (Sigma) for about 10 min, depend-
ing on digesting conditions. The ventricles were cut off
and minced in solution, followed by pipetting to disasso-
ciate the cells, and then filtered through a nylon mesh to
remove big pieces of undigested tissues. The GFP+ cells
represented CDCs or their derived cells, which were
carefully counted. The survival rate = 100% × (number of
survived GFP+ cells/1 × 105).
Inflammatory cell infiltration analysis
Similar to the method previously described [6], mouse
hearts in the different groups were digested at 48 h after
MI. Using a 30-μm filter, the small cells (<30 μm) were
collected while most of the cardiomyocytes (>30 μm)
were discarded. Inflammatory cell populations were
analyzed by BD Accuri™ C6 Cytometer. Representative
contour plots were made showing infiltrating monocyte
cells in the heart, as defined by the expression of
Ly6Chigh and CD11b+. Data were analyzed by FlowJo
software.
Histology
Hearts were fixed with 4% paraformaldehyde, subse-
quently embedded in paraffin, and cut to 5-μm thick
sections. Similar to the method previously described
[14], quantitative morphometric analysis with Masson’s
trichrome staining was performed. The area of infarct
size was calculated by dividing the midline length of the
infarcted LV wall by the midline length of total LV wall
[15]. The percentage of the fibrotic area of the left ven-
tricle was measured using Image J software. Individuals
conducting the experiment were blinded to the experi-
mental groups. To observe the survival of GFP+ CDCs
in hearts, anti-GFP, anti-sarcomeric tropomyosin
(Sigma), and DAPI for nuclei were used to stain the
heart tissue. To trace CDC differentiation, immunostain-
ing against GFP, sarcomeric tropomyosin (a cardiomyo-
cyte marker), von Willebrand factor (vWF; an endothelial
cell marker), and α-smooth muscle actin (α-SMA; a
smooth muscle cell marker) were performed.
The assessment of CDC survival in vitro
CDCs were cultured in serum-free media for 24 h and
H2O2 (30 μmol/L for 24 h) was used to induce CDC
apoptosis. CDCs were pretreated with MET at different
dosages (1, 10, 100, 1000, 3000, or 5000 μmol/L) and for
different time periods (15, 30, 60, 120, and 180 min) for
inhibiting H2O2-induced CDC apoptosis. Administration
of MET at 100 μmol/L for 60 min was selected for the
experiment. AICAR (500 μmol/L for 60 min) was used
to activate AMPK, and compound C (CC; 20 μmol/L for
4 h) was used for inhibiting AMPK [8]. Cell viability was
detected using the CCK8 Cell Proliferation Assay Kit
(Dojindo). CCK8 reagent (10 μL) was added to each well
and incubated for 2 h at 37 °C. The number of viable
cells was calculated by absorbance measurements at
450 nm. For evaluating CDC apoptosis, the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) assay was undertaken. Apoptosis was
also quantified by flow cytometry (FACScan; Dickinson
and Company) after cells were stained with annexin V
and propidine iodide (PI) by using an AnnexinV-FITC
Apoptosis Detection Kit (Sigma) [6].
Western blot analysis
Total cellular extracts were obtained by cell lysis, as
described previously [6]. Briefly, aliquots of cell lysates
containing 50 μg protein were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The protein was then transferred from the gel to
polyvinylidene fluoride membranes, which were incu-
bated with primary antibodies for 1 h at room
temperature and then at 4 °C overnight. After washing
with Tris-buffered saline Tween-20, the membranes were
incubated with horseradish peroxidase (HRP)-conjugated
secondary antibody diluted 1:5000 (Cell Signaling Tech-
nology) and the signals were detected by chemilumines-
cence. Quantification of the bands was carried out using
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Quantity One software. To ensure equal loading of the
protein, GAPDH was used as an endogenous control.
Reagents
1-Dimethylbiguanide hydrochloride (metformin hydro-
chloride), 5-aminoimidazole-4-carboxamide ribonucleoside
(AICAR; an AMPK activator), 6-(4-(2-piperidin-1-yl-eth-
oxy)-phenyl)-3-pyridin -4-yl-pyyrazolo(1,5-a) pyrimidine
(compound C; an AMPK inhibitor) and H2O2 were pur-
chased from Sigma-Aldrich (USA). Antibodies against
phospho-AMPK-Thr-172 and AMPK were purchased from
Cell Signaling Technology. The antibodies against
endothelial nitric oxide synthase (eNOS) and
phospho-eNOS-Ser-1177 were purchased from Santa
Cruz Biotechnology.
Statistical Analysis
Data are reported as the mean ± SEM. For analysis of
differences between two groups, a student’s t test was
performed. For multiple groups, one-way analysis of
variance (ANOVA) with post-hoc comparisons by the
Tukey’s test was used. Data were analyzed using SPSS
Fig. 1 The culture and characterization of cardiosphere-derived cells. a Cells grew from the explant on top of a layer of stromal-like cells after
7 days. Cardiospheres formed after 4 days in suspension culture on poly-D-lysine-coated dishes. Cardiosphere-derived cells become confluent
after 5 to 7 days. Scale bar = 100 μm. b Flow cytometric analysis showed that cardiosphere-derived cells were positive for CD29, CD105, and
CD90, and negative for CD31, CD45, and CD34. GFP green fluorescent protein
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13.0 for Windows (SPSS, Chicago, IL, USA). A P value
<0.05 was considered significant.
Results
Characterization of cell phenotypes
CDCs were isolated and expanded from transgenic
β-actin-GFP mice with a protocol similar to that
reported previously [12]. GFP labeling was used to
trace the CDCs after transplantation into the myo-
cardium. As shown in Fig. 1a, the partially enzymati-
cally digested ventricular explants spontaneously
yielded outgrowth cells (explant-derived cells). These
cells were harvested and formed three-dimensional
cardiospheres. Subsequent replating of cardiospheres
Fig. 2 Combination of metformin (MET) treatment and cardiosphere-derived cell (CDC) transplantation improved cardiac function in myocardial
infarction (MI) mice. a Representative echocardiographic images of hearts with different treatments at 4 weeks post-MI. Scale bar = 2 mm. b Heart
rates were controlled to be similar in different groups. c,d Left ventricular ejection fraction and fraction shortening at 4 weeks post-MI. n = 8. Data
were analyzed by one-way ANOVA with post-hoc comparisons by the Tukey’s test. *P < 0.05 vs. sham; #P < 0.05 vs. MI + phosphate-buffered saline
(PBS); &P < 0.05 vs. MI + MET; %P < 0.05 vs. MI + CDC. MET/CDC MET-pretreated CDCs
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on adherent culture dishes yielded CDCs which were
expanded and used for the experiments. Flow cytom-
etry analysis revealed that CDCs expressed CD29
(98.1%), CD105 (99.2%), and CD90 (19.6%), but were
negative for CD31, CD45, and CD34 (Fig. 1b), which
is consistent with the characteristics previously
reported [16].
To identify the multi-differentiation potential of
the CDCs, permanent ligation of the left anterior de-
scending coronary artery was performed to induce
MI injury, and CDCs were intramyocardially injected
into the infarct border zone. Immunostaining was
performed 4 weeks post-transplantation. As shown
in Additional file 1 (Figure S1), GFP staining was
used to identify the transplanted CDCs, and a few
CDCs were demonstrated to express tropomyosin,
vWF, or α-SMA, indicating that CDCs could give
rise to cardiomyocytes, endothelial cells, and smooth
muscle cells, although the differentiation efficacies
were very low.
MET augmented the therapeutic effect of CDC
transplantation against MI
CDCs were pretreated with MET at 100 μmol/L for
60 min before transplantation. The recipient wild-
type C57 mice were randomly assigned to different
experimental groups. MI was induced and 1 × 105
CDCs were intramyocardially injected into the
infarct border zone immediately after MI. MET
treatment was induced by intraperitoneal injection of
MET at a dose of 125 mg/kg/day for a week. The
initial areas at risk (i.e., the area of ischemia) of the
infarcted hearts in the different groups with MI
injury were comparable (36.18 ± 1.73%; Additional
file 2: Figure S2A). Echocardiography was performed
4 h after MI induction and showed that the post-MI
mice had an equivalent reduction in EF% (Additional
file 2: Figure S2B).
At 4 weeks post-MI, treatment with CDCs or MET
alone modestly improved the cardiac function. Trans-
plantation with MET-pretreated CDCs, with or without
Fig. 3 Combination of metformin (MET) treatment and cardiosphere-derived cell (CDC) transplantation reduced infarct size in myocardial infarction
(MI) mice. a1 Representative images of Masson’s trichrome staining for heart tissue obtained from hearts with different treatments at 4 weeks post-MI.
Scale bar = 1 mm. a2 Graphic representation of the left ventricular (LV) infarct size calculated as the ratio of midline length of the infarcted LV wall to
the midline length of total LV wall (n = 5). b Representative images (b1) and quantification (b2) of the fibrotic area in the infarct area 4 weeks post-MI.
Scale bar = 200 μm. c Representative images (c1) and quantification (c2) of the fibrotic area at the infarct border zone 4 weeks post-MI. Scale bar =
100 μm. n = 5. Data were analyzed by one-way ANOVA with post-hoc comparisons by the Tukey’s test. *P < 0.05 vs. MI + phosphate-buffered saline
(PBS); #P < 0.05 vs. MI +MET; &P < 0.05 vs. MI + CDC. MET/CDC MET-pretreated CDC
Yue et al. Stem Cell Research & Therapy  (2017) 8:17 Page 6 of 12
MET injection, significantly improved the cardiac func-
tion compared with the other groups (Fig. 2). Mean-
while, Masson’s trichrome staining was used to measure
infarct size and fibrosis. CDCs or MET treatment
slightly reduced infarct size at 4 weeks post-MI. Trans-
plantation with MET-pretreated CDCs, with or without
MET injection, further reduced MI-induced infarct size
(Fig. 3a). In addition, the percentage of fibrotic areas
both in the total infarction and peri-infarct zone were
significantly reduced in these two groups (Fig. 3b and c).
These data suggested that MET pretreatment augmented
the therapeutic effect of CDC transplantation against MI
injury.
MET pretreatment promoted CDC survival in post-MI
heart
The heart tissue was harvested at different time points
after CDC transplantation. Immunostaining was per-
formed to identify the surviving CDCs with GFP label-
ing. As shown in Fig. 4a, the GFP+ CDCs were observed
in heart tissue 7 days post-transplantation, and signifi-
cantly more GFP+ cells were seen in the MET-pretreated
groups. It is known that death of stem cells predomin-
antly occurs within the first 24 h post-transplantation
into the myocardium. Thus, the hearts were enzymati-
cally digested at 24 h post-transplantation and the GFP+
cells were carefully quantified. CDCs survived more
Fig. 4 Metformin (MET) treatment increased cardiosphere-derived cell (CDC) survival after transplantation into post-myocardial infarction (MI)
hearts. a Representative images of survived CDCs in hearts at 7 days after transplantation. Heart tissue was immunostained for tropomyosin
(red), green fluorescent protein (GFP) (green) and DAPI (blue). Scale bar = 100 μm. b Post-MI hearts with CDC transplantation were enzymatically
digested, and small cells from the heart (<30 μm diameter) were collected after depletion of cardiomyocytes. As indicated with the white arrows,
GFP-positive cells represent surviving CDCs under fluorescence microscope. Scale bar = 50 μm. c The percentage of surviving CDCs out of the
total transplanted CDCs at 7 days post-transplantation. n = 5. Data were analyzed by one-way ANOVA with post-hoc comparisons by the Tukey’s
test. *P < 0.05 vs. MI + CDC. MET/CDC MET-pretreated CDC
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when pretreated with MET before transplantation, and a
combination of intraperitoneal administration of MET
further increased the CDC survival (survival rates of
1.08 ± 0.14% vs. 2.15 ± 0.15% vs. 2.46 ± 0.17%, for MI +
CDC, MI +MET/CDC, and MI +MET +MET/CDC,
respectively; n = 4; P < 0.05) (Fig. 4b and c).
Effects of MET-pretreated CDC transplantation on post-MI
myocardial inflammation
We next investigated the inflammatory cell infiltration
using flow cytometry at 48 h after MI. The percentage of
CD11b+/Ly6Chigh cells was robustly upregulated by MI
injury, which was reduced by MET treatment or CDC
transplantation. However, the combination of MET and
CDC transplantation did not exert stronger anti-
inflammatory effects (Fig. 5), suggesting that the
enhanced CDC survival and function induced by MET
might not be associated with the inflammatory response.
MET attenuated oxidative stress-induced CDC apoptosis
via AMPK activation
Oxidative stress is known to be a major factor causing stem
cell apoptosis in the transplantation microenvironment of
the post-MI heart. CDCs were treated with 30 μmol/L
H2O2 for 24 h to induce oxidative stress. CDC apoptosis
was detected with TUNEL staining and flow cytometric
analysis following annexin V and PI staining. CDC viability
was measured with cell counting kit-8 (CCK8) assay. As
shown in Fig. 6a and b, H2O2 induced CDC apoptosis and
decreased CDC viability. MET pretreatment (100 μmol/L
for 60 min) significantly decreased the TUNEL+ CDCs and
annexin V+/PI– CDCs subjected to H2O2 insult. The
decreased CDC viability induced by H2O2 was also largely
restored by MET (Fig. 6c). When the AMPK inhibitor
compound C (CC; 20 μmol/L) was used to pretreat the
CDCs 30 min before MET administration, the anti-
apoptotic effect of MET was blunted. The AMPK activator
AICAR also reduced H2O2-induced CDC apoptosis, which
was blocked by CC pretreatment (Fig. 6a and b). These
data suggest that MET attenuated oxidative stress-induced
CDC apoptosis via activation of AMPK.
AMPK/eNOS signaling pathway mediated the pro-survival
effect of MET on CDCs
To further determine how MET resulted in AMPK activa-
tion, α-AMPK phosphorylation in CDCs was evaluated
Fig. 5 The effect of metformin (MET) treatment on the inflammatory response in post-myocardial infarction (MI) hearts. Representative contour
plots (a) and quantification (b) of infiltrating monocyte population (Ly6Chigh/CD11b+) in cells isolated from infarcted hearts at 48 hours post-MI
analyzed by FACS analysis. n = 5. Data were analyzed by one-way ANOVA with post-hoc comparisons by the Tukey’s test. *P < 0.05 vs. Sham;
#P < 0.05 vs. MI + phosphate-buffered saline (PBS). MET/CDC MET-pretreated cardiosphere-derived cells
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with Western blotting analysis. The total AMPK pro-
tein expression was comparable among each experi-
mental group. Compared with control, H2O2
treatment did not change the expression of phosphor-
ylated α-AMPK at Thr-172 in CDCs. The level of
phosphorylated α-AMPK significantly increased when
CDCs were treated with MET or AICAR, which was
blocked by pretreatment with the AMPK inhibitor CC
(Fig. 7a). As the downstream target of AMPK, eNOS
is known to regulate cell apoptosis. Our data show
that the level of phosphorylated eNOS at Ser-1177
expression was slightly decreased by H2O2 treatment.
MET and AICAR significantly increased the eNOS
phosphorylation, which was also blocked by pretreat-
ment with CC (Fig. 7b). These data suggest that the
MET-induced pro-survival effect against oxidative
stress might be associated with the AMPK/eNOS
signaling pathway.
Discussion
Much progress has been made in the field of stem cell
transplantation for treating MI, but challenges such as
poor cell survival in the harsh transplantation micro-
environment greatly limit its therapeutic effect. In this
study, we combined MET treatment and CDC trans-
plantation for treating MI injury in mice, and found that
MET improved CDC survival thereby enhancing its
therapeutic effect after transplantation. Our data showed
that the anti-apoptotic function of MET on CDCs was
associated with AMPK activation and eNOS
Fig. 6 Metformin (MET) treatment exerted an anti-apoptotic effect on CDCs subjected to oxidative stress by activating AMPK. a1 Annexin V-PI
double staining assay of CDCs treated with H2O2, analyzed by flow cytometric analysis. a2 Average percentages of apoptotic CDCs. n = 9.
b Representative images (b1) and quantification (b2) of TUNEL staining in CDCs subjected to H2O2 treatment. Cell nuclei were stained with DAPI (blue)
and TUNEL+ nuclei were labeled with TMR (green). TUNEL positive rate = (TUNEL-positive nuclei/DAPI-positive nuclei) × 100%. n = 12. Scale bar = 30 μm.
c Cell viability of CDCs detected with CCK8 analysis. The data were normalized to 100% of the control group. Data were analyzed by one-way ANOVA
with post-hoc comparisons by the Tukey’s test. *P < 0.05 vs. control; #P < 0.05 vs. H2O2. CC compound C
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phosphorylation. Since MET is a safe medication in clin-
ical practice, combination of MET treatment with stem
cell therapy is of clinical significance to treat MI
patients.
The fact that CDC transplantation elicits cardioprotec-
tive effects has been shown in small and large animals,
and in patients with MI injury. Aside from autologous
CDC transplantation, ‘off-the-shelf ’ allogeneic human
CDCs are being tested clinically in the ALLSTAR and
DYNAMIC trials [17]. CDCs have multi-differentiation
capacity in vivo, which was confirmed in our study. It is
also known that the therapeutic effect of CDCs is mainly
mediated by the paracrine effect rather than by direct
differentiation [18, 19]. CDCs were reported to stimulate
increased myocyte proliferation compared with other
stem cell types such as bone marrow-derived mesenchy-
mal stem cells [20], probably because CDCs exhibited a
balanced profile of paracrine factor production [21]. The
effects of both the paracrine effect and differentiation
rely on the quantity of the surviving CDCs. In our study,
we speculate that these functions of CDCs were im-
proved when more post-transplanted CDCs survived
with MET treatment. The reduced infarct size might be
due to decreased myocyte apoptosis and increased new
cardiomyocyte formation.
Despite the progress in recent years, the survival of
transplanted cells in infarcted myocardium is still poor
[5, 22]. Previous studies reported that only <5% of post-
transplanted stem cells survive in the peri-infarct area.
Factors such as ischemia, oxidative stress, and inflamma-
tion hamper stem cell survival in the post-MI heart.
MET is reported to attenuate inflammation [11], but our
data indicated that the pro-survival effect of MET on
CDCs in the infarcted heart was less likely associated
with its influence on inflammation. Oxidative stress al-
ters the balance of the production and elimination of
intracellular oxygen-free radicals and results in over-ac-
cumulation of reactive oxygen species (ROS), which are
major factors inducing the apoptosis of transplanted stem
cells [23]. Efforts including modification of cell survival-
associated genes have been made [5], but these methods
are far from clinical use. We demonstrated that MET pre-
treatment exerted an anti-apoptotic effect on CDCs sub-
jected to oxidative stress in vitro, and that MET promoted
the survival of post-transplantation CDCs in vivo. The
combination of MET and CDC transplantation exerted a
significantly greater effect on increasing cardiac function
and reducing infarct size of the infarcted heart, indicating
that MET is a ready-to-use medication for augmenting
the therapeutic effect of stem cell transplantation.
MET is recognized to activate AMPK, which is essential
for keeping the balance of energy production and metab-
olism in various tissues, thereby modulating cell apoptosis.
MET can also exert cardioprotective effects independently
Fig. 7 Metformin (MET) treatment increased phosphorylation of AMP-activated protein kinase (AMPK)/endothelial nitric oxide synthase (eNOS)
in CDCs. Representative blots (a1) and quantification (a2) of AMPK phosphorylation. AMPK phosphorylation was represented as the ratio
of phosphorylated α-AMPK at Thr-172 to total AMPK of CDCs. Representative blots (b1) and quantification (b2) of eNOS phosphorylation.
eNOS phosphorylation was represented as the ratio of phosphorylated eNOS at Ser-1177 to total eNOS of CDCs. Data were analyzed by
one-way ANOVA with post-hoc comparisons by the Tukey’s test. *P < 0.05 vs. control; #P < 0.05 vs. H2O2. CC compound C
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of anti-hyperglycemic effects. MET-induced AMPK acti-
vation exerts protective effects against acute oxidative
stress-induced injury in cardiomyocytes [24]. AMPK
works as a protein kinase to activate eNOS by phosphoryl-
ating eNOS at Ser-1177 [25]. As a potent protective sig-
naling molecule, eNOS is expressed in vascular
endothelial cells, cardiomyocytes, and different types of
stem cells. Overexpression of eNOS generates low
amounts of NO, which regulates the apoptosis of embry-
onic stem cells [26]. MET improves cardiomyocyte sur-
vival under ischemia/perfusion injury, which is associated
with increases in AMPK and eNOS phosphorylation [13].
We demonstrated that MET increased AMPK and eNOS
phosphorylation in CDCs. Another AMPK activator,
AICAR, showed similar effects to MET. These data sug-
gest that the MET-induced anti-apoptotic effect on CDCs
might be associated with the AMPK/eNOS pathway.
Conclusions
Our study reveals that MET treatment significantly
enhances the therapeutic effect of CDC transplantation
against MI injury. The pro-survival effect of MET on
CDCs might be through an AMPK-eNOS-dependent
mechanism. Since MET is a safe and ready-to-use medi-
cation, combination of MET treatment and stem cell
therapy may be a promising strategy in clinical practice.
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and DAPI was used for identifying nuclei. Scale bars = 20 μm. DAPI 4′,6-
diamidino-2-phenylindole. (PDF 178 kb)
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(AAR) of mice hearts 4 h post-MI. (A2) Quantitative data for AAR and
area not at risk (ANAR) of mice hearts 4 h post-MI. (B) Averaged ejection
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